Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CD22-specific universal CAR-expressing T lymphocytes UCART22

A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CD22 with potential immunomodulating and antineoplastic activities. Upon transfusion, allogeneic CD22-specific universal CAR-expressing T lymphocytes UCART22 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic gene-edited CAR T cells UCART22
allogeneic TALEN gene-edited CAR T-Cells UCART22
allogenic engineered T cells expressing anti-CD22 CAR UCART22
UCART22 cells
Code name:UCART 22
UCART-22
UCART22
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search